Product
PF-06863135 + Pomalidomide
Aliases
BCMA-CD3 bispecific antibody + pomalidomide, PF-06863135 + pomalidomide
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
MAGNETISMM-1 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)Status: Completed, Estimated PCD: 2024-01-19